Member Info for RiskIsReward

We had CE mark for so long and EU was our target market but till date no sales. Honestly I do not expect much sales from Uk even if we get CTDA. I think it’s waste of money and time.
Budd would only answer those questions which he is comfortable and ignore others. Do not waste your time by posting questions.

Upside: This could rocket the sp to moon (£1)
Some POC sales in EU
US DOD confirmation
good AIHL revenue forecast

downside:
No POC sales
US DOD opportunity lost
Slow adaptation of AIHL with poor short term revenue forecast.
instant sp crash to a single digit as we wont be generating enough revenue to keep lights on and may need to raise cash again.
both scenarios are very much possible, very high risk share.

Did you read the document and to find out the delivery schedule for genedrive devices?
The procurement for genedrive devices is slated for June 2022. so i thought we could recive an order sooner to prepare for delivery.

GENE DRIVE - JHBI - Hardware -
Genedrive (devices) NGB 2022 Biomeme / Philadelphia, PA SS / FFP RDECOM, Natick, MA Mar 2022 Jun 2022 57 6.491 Y
GENE DRIVE - JHBI - Hardware -
Genedrive (devices) USAF 2022 Biomeme / Philadelphia, PA SS / FFP RDECOM, Natick, MA Mar 2022 Jun 2022 85 6.494 Y
GENE DRIVE - JHBI - Hardware -
Genedrive (devices) USN 2022 Biomeme / Philadelphia, PA SS / FFP RDECOM, Natick, MA Mar 2022 Jun 2022 3 6.667 Y

The recent RNS has desrisked sp. Risk vs Reward at current level is very good.

https://comptroller.defense.gov/Portals/45/Documents/defbudget/fy2022/budget_justification/pdfs/02_Procurement/ROC_Vol1_DW_PROC_PB22_Justification_Book_Final.pdf

This is the next big news!!

Because department of defense fiscal year (FY) 2022 budget estimates inludes Genedrive:
https://comptroller.defense.gov/Portals/45/Documents/defbudget/fy2022/budget_justification/pdfs/02_Procurement/ROC_Vol1_DW_PROC_PB22_Justification_Book_Final.pdf

One thing for sure is it was a sale not trial as some are saying.
A deployment means commericalised and revenue started although it may be small amount. It is just first adaptation and rest would just follow as this test is first of its of kind.
David Budd atlast sold something and it can only go one way from here.

sp has to do more than 100% to get to my break even price. Looks like quite a lot are ready to get out as soon as they break even.. I don’t blame you guys as I think same after being in this for 2 years and see myself going from blue to red on multiple occasions . Lots of lessons learned.

It’s only .52% short.. which is 478,400. Shares.. less than half a million not hard to buy back from market I guess..

I think Budd is holding some interesting numbers for his presentation on 31st and I for the first time believe SP is going to rocket on 31st unlike previous presentations..
Can David Budd prove me right for atleast once? fingers crossed.

They have funds to run till end of the year atleast as far as i know from the recent fund raise and their burn rate.
good news the revenue is now coming from AIHL, it would only increase as implementation increases.. This can only get better from here..

just need some orders or sales from US DOD / POC in next 3 months.. then this could send the SP to moon..

Atlast some income is coming from AIHL. A big releif to all LTH!!
Would have been great if Budd could have provided a bit more details on revenue and future expansion details to other NHS trusts. Best RNS in the history of GDR i think.

To Support the AIHL product launch in other countries we need money to follow country specific studies and approvals and it could well take years again.. Budd made it clear that we did not raise enough money in out last round for that...

First let us sell in UK to fund our high expenses otherwise we are far off off from another raise..
if you're here for more than 2 years, you should know by now how GDR makes money to run company.

Raffs60 makes me laugh.. did you see where they are now despite making huge sales.
you need take more examples, checkout ODX where they are now compared to prepandemic..
we are 2 years into Pandemic and failed to generate sales.. did two placings.. and curretly 25% below placing price
Where is the comparison?

All I'm trying to say is we need sales and revenue to support our high costs.
I never understood Budd, He forged so many distribution agreements and none of them any money.. very sad state..
Budds needs to bring in some sales..

Hope the next news is sales/revevnue one and a significant one to change the future of the company.
Tired of approvals and distribution RNS for last 2 years which never transpired into revenue...

news can land antime.. could be tomorrow or next week or next month or next year...

Need to free up funds, bargain territory..
So won’t be here for too long

@radius - good buy. anthing below 120 is a bargain.
i think 2022 would be great year for Ilika, with Stereax facility now ready and awaiting commercial deals in Q2 2022.
Not to forget the much awaited updates on Goliath. £10m from last placing was ear marked for Goliath development.

here is the warrants list from recent RNS on 30th december, its long list one.. in total 5.58m shares
There is further RNS on 18th Jan Exececise of warants - 376,509 shares (not sure if that was from below list

Warrant Holder No of warrants Exercise Price Current expiry date Extended expiry date
Hemant Poddar 200,000 £0.30 31/12/2021 31/12/2022
Christian St. John-Dennis 200,000 £0.30 31/12/2021 31/12/2022
Shishir Poddar 600,000 £0.30 31/12/2021 31/12/2022
Hemant Poddar 240,000 £0.40 31/12/2021 31/12/2022
Christian St. John-Dennis 240,000 £0.40 31/12/2021 31/12/2022
Rajesh Kedia 140,000 £0.40 31/12/2021 31/12/2022
Shishir Poddar 900,000 £0.40 31/12/2021 31/12/2022
Puruvi Poddar 320,000 £0.40 31/03/2022 31/03/2023
Kien Huynh 160,000 £0.40 31/03/2022 31/03/2023
Hemant Poddar 240,000 £0.40 31/12/2022 31/12/2023
Christian St. John-Dennis 240,000 £0.40 31/12/2022 31/12/2023
Rajesh Kedia 240,000 £0.40 31/12/2022 31/12/2023
Shishir Poddar 900,000 £0.40 31/12/2022 31/12/2023
Puruvi Poddar 480,000 £0.40 31/03/2023 31/03/2024
Kien Huynh 480,000 £0.40 31/03/2023 31/03/2024
Total 5,580,000

On 2nd december half yearly results RNS states
"The Company's only debt is the pre-IPO issued convertible loan notes outstanding of £1.17 million which are convertible at the IPO price of £0.45 per share"

They need to, because they have mention in RNS some interest from partners around Europe opportunities and the validation is in progress.
now we have approval, What happened the interested partners and validation? how long will it take?